Startups
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.
Overview
Location
United States, Maryland, Beltsville
Employees
51-200
Total raised
$160M
Founded date
2015
Investors 8
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Sofinnova Investments | sofinnova.com | |
| OrbiMed | orbimed.com | |
| Timefolio Capital | timefoliocapital.co.kr | |
| Taiho Ventures | taihoventures.com | |
| Canaan Partners | canaan.com | |
| SymBiosis | symbiosis.vc | |
| Bay City Capital | baycitycapital.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jan 6, 2016 | Series A round | $67M |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 10, 2025 | [CIIE] Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply | (Yicai) Nov. 10 -- Simcere Pharmaceutical Group showed its redefined cross-border collaboration model at the eighth China International Import Expo, with the Chinese company to soon start manufacturing in China an insomnia drug it licensed ... |
| Mar 5, 2024 | NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances | |
| Oct 4, 2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |
| Oct 19, 2021 | NextCure : Announces Three New Members of its Scientific Advisory Board | BELTSVILLE, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-rela... |
| Oct 4, 2021 | NextCure : Announces New Appointments to its Board of Directors | BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-rela... |
| Oct 4, 2021 | NextCure : Announces New Appointments to its Board of Directors (Form 8-K) | NextCure Announces New Appointments to its Board of Directors BELTSVILLE, Md., October 4, 2021 - NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunom... |
| May 9, 2019 | Four biotech companies announce pricings of IPOs, looking to raise more than $300M | NextCure, based in Beltsville, Maryland, said Wednesday that it had priced its IPO of 5 million shares at $15 each. Montreal-based Milestone said it had priced its 5.5 million share IPO also at $15 per share. Cortexyme, based in South San F... |
| Nov 13, 2018 | NextCure Nabs $93M Series B Funding | BELTSVILLE, MD, NextCure today announced the completion of a $93 million series B equity financing. >> Click here for more funding data on NextCure >> To export NextCure funding data to PDF and Excel, click here NextCure,... |
| Nov 13, 2018 | NextCure Completes a $93M Series B Financing |
Show more
Reviews 0
FAQ about NextCure, Inc.
When was NextCure, Inc. founded?
NextCure, Inc. was founded in 2015.
How much funding has NextCure, Inc. raised?
NextCure, Inc. has raised $160M in total across 2 funding rounds.
What funding rounds has NextCure, Inc. raised?
Parsers VC lists 2 funding rounds of NextCure, Inc., among them a Series A round of $67M on Jan 6, 2016.
Who has invested in NextCure, Inc.?
Parsers VC lists 8 investors of NextCure, Inc., among them Sofinnova Investments, OrbiMed and Timefolio Capital.
What has the press written about NextCure, Inc.?
Parsers VC has collected 14 articles mentioning NextCure, Inc., among them “[CIIE] Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply” (Nov 10, 2025) and “NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances” (Mar 5, 2024).
Is NextCure, Inc. still active?
Yes, NextCure, Inc. is active; its latest activity on Parsers VC dates from May 12, 2026.